Q2 FY2026 EarningsQ2 FY26 results missed consensus on the top line but beat on EPS due to non-cash warrant valuation gains. Revenue was $0.051M vs. $0.08M expected, while GAAP EPS was -$0.07 vs. the -$0.08 mean estimate. The operating loss widened to $5.57M as R&D spending accelerated to support the Acclaim Cochlear Implant pivotal trial. Management announced the submission of the first PMA module, but a going concern warning remains as cash of $19.7M is only expected to fund operations through Q1 FY27.
Financial report interval: 2026.03.30 - 2026.06.30
Preview: Envoy Medical(COCH) predict that the Revenue is 51 K (-34.62%), Miss estimate;the EBIT is -5.569 M (-9.84%), Beat estimate;the EPS is -0.07 (+78.13%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B34.62%
0.00B2.56%
-0.00B37.18%
EBITExceed expectations
-0.01B9.84%
-0.01B13.07%
+0.00B3.23%
EPSExceed expectations
-0.0778.13%
-0.0875.00%
+0.01003.13%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf